Beyond elucidating ARL5B's pivotal role in tumor lipid metabolism, our findings establish a theoretical framework for targeting this pathway and propose ARL5B as a potential therapeutic vulnerability for metabolic intervention strategies in ESCC. This evidence concerns the gene ARL5B and esophageal squamous cell carcinoma.